My Treatment Approach: Interpreting the Data for Early-Stage HR+ Breast Cancer

home / insights / my-treatment-approach-interpreting-the-data-for-early-stage-hr-breast-cancer

In this series, we will discuss recent advances in the treatment of HR+ breast cancer. We will review two patient cases and discuss our treatment approach to illustrate how we are incorporating recent trial data into our clinical practice.

EP. 1: Clinical Case 1: High-Risk Early-Stage HR+ Breast Cancer

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

June 29th 2023

Stephanie Graff, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.

EP. 2: Risk Factors and the Treatment Plan

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

June 29th 2023

Rachel Layman, MD, describes her impression of the case and discusses risk assessment and a treatment plan for the patient.

EP. 3: Endocrine Therapy for Early-Stage Breast Cancer

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

July 6th 2023

Expert medical oncologists provide an overview of current endocrine therapy approved for early-stage breast cancer.

EP. 4: Key Findings from the monarchE Trial

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

July 6th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the monarchE trial, which evaluated abemaciclib plus endocrine therapy for HR+, HER2 negative, node positive, high-risk early breast cancer.

EP. 5: Individualizing Care with CDK 4/6 Inhibitors

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

July 13th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss how to individualize care with CDK4/6 inhibitors in patients with high-risk early breast cancer.

EP. 6: Age-Dependent Results With CDK 4/6 Inhibitors

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

July 13th 2023

Experts in breast oncology review age-dependent outcomes with CDK 4/6 inhibitors.

EP. 7: Dosing CDK 4/6 Inhibitors

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

July 20th 2023

Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.

EP. 8: Implementing Trial Data to Our Practice

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

July 20th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss how they would apply the results of the monarchE trial to clinical case scenarios.

EP. 9: Selecting Endocrine Therapy in BRCA1/BRCA2+ Breast Cancer

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

July 27th 2023

Experts in breast oncology discuss how they select endocrine therapy in BRCA1/BRCA2+ breast cancer.

Rachel Layman, MD, an expert on breast cancer

EP. 10: Clinical Case 2: High-Risk Early-Stage HR+ Breast Cancer

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

July 27th 2023

Rachel Layman, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.

Stephanie Graff, MD, FACP, an expert on breast cancer

EP. 11: Risk of Recurrence

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

August 3rd 2023

Stephanie Graff, MD, describes her impression of the case and discusses the risk for recurrence in this particular patient.

EP. 12: Key Findings from the NATALEE Trial

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

August 3rd 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.

EP. 13: Impact of Trial Data on Clinical Practice

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

August 10th 2023

Expert medical oncologists talk about the impact of NATALEE trial data on their medical practice.

EP. 14: Managing Toxicities and Adverse Events of CDK 4/6 Inhibitors

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

August 10th 2023

Stephanie Graff, MD, and Rachel Layman, MD, review common toxicities and adverse effects to watch out for with endocrine therapy and CDK4/6 inhibitors, and how to manage these.

EP. 15: What is on the Horizon for Adjuvant Therapy in Early-Stage Breast Cancer?

Stephanie L. Graff, MD, FACP;Rachel Layman, MD

August 17th 2023

Expert medical oncologists take a step into the future and discuss developments within the adjuvant setting of early-stage breast cancer they are most excited about.